Revenue Up 9%, Dividend Up 12%, Stock Down 65%

Key Takeaways

• Revenue grew 9% YoY, dividend rose 12% despite market slump
• Shares down 65% since 2021, trading at 8× EBITDA
• Net cash equals sizable portion of market capitalization
• Embedded in 18,000 French pharmacies, creating high switching costs
• Peers trade above 12× EBITDA, highlighting valuation gap

Pulse Analysis

The French pharmacy software sector is a niche yet critical component of Europe’s healthcare ecosystem. By automating drug dispensing, inventory control, and reimbursement processes for roughly 18,000 pharmacies, the firm has entrenched itself in daily operations, creating a barrier that rivals find hard to breach. This embeddedness translates into predictable recurring revenue and a low churn rate, traits that investors prize in SaaS‑style businesses. Moreover, the company’s focus on compliance with the national health insurance system adds regulatory defensibility, further cementing its moat.

Financially, the company posted a 9% year‑over‑year revenue increase and lifted its dividend by 12%, signaling confidence in cash generation. It trades at about 15× forward earnings and 8× EBITDA, well below the 12‑plus multiple typical for comparable European health‑tech firms that were recently taken private. Net cash on hand represents a material portion of its market cap, providing a cushion against downside risk and funding for future product enhancements. The dividend raise, coupled with high‑single‑digit profit compounding, underscores a resilient balance sheet despite a four‑year share price slide.

For investors, the key question is whether the 65% price decline reflects genuine operational concerns or a market overreaction to sector fatigue. The firm’s deep integration with pharmacies, strong cash position, and attractive valuation suggest the latter. However, risks remain, including potential regulatory shifts in France’s reimbursement framework and the concentration of ownership among pharmacy customers, which could pressure governance. Overall, the mispricing creates a potential catalyst for a value‑oriented play, especially for those comfortable with a longer investment horizon and the nuances of European health‑tech dynamics.